$MED
MEDIFAST INC Stock $med

$med Overview Financials Valuation SEC Filings Company Website

2023 Q4 Form 10-Q Financial Statement

#000162828023037080 Filed on November 06, 2023

Income Statement

Concept	2023 Q4	2023 Q3
Revenue	$191.0M	$235.9M
YoY Change	-43.36%	-39.58%
Cost Of Revenue	$49.65M	$58.49M
YoY Change	-52.1%	-45.61%
Gross Profit	$141.4M	$177.4M
YoY Change	-39.48%	-37.29%
Gross Profit Margin	74.01%	75.2%
Selling, General & Admin	$131.5M	$151.9M
YoY Change	-34.19%	-35.29%
% of Gross Profit	93.01%	85.62%
Research & Development	$1.200M	$1.300M
YoY Change	0.0%	18.18%
% of Gross Profit	0.85%	0.73%
Depreciation & Amortization	$3.307M	$3.500M
YoY Change	11.95%	22.81%
% of Gross Profit	2.34%	1.97%
Operating Expenses	$132.7M	$151.9M
YoY Change	-33.98%	-35.29%
Operating Profit	$8.676M	$25.51M
YoY Change	-73.39%	-47.03%
Interest Expense	$1.176M	$1.033M
YoY Change	-746.15%	-495.79%
% of Operating Profit	13.55%	4.05%
Other Income/Expense, Net	-$50.00K	$1.040M
YoY Change	455.56%	-474.1%
Pretax Income	$9.802M	$26.55M
YoY Change	-69.75%	-44.55%
Income Tax	$3.767M	$3.418M
% Of Pretax Income	38.43%	12.87%
Net Earnings	$6.035M	$23.13M
YoY Change	-77.24%	-36.02%
Net Earnings / Revenue	3.16%	9.81%
Basic Earnings Per Share		$2.12
Diluted Earnings Per Share	$0.55	$2.12
COMMON SHARES
Basic Shares Outstanding	10.89M shares	10.89M shares
Diluted Shares Outstanding		10.93M shares

Balance Sheet

Concept	2023 Q4	2023 Q3
SHORT-TERM ASSETS
Cash & Short-Term Investments	$150.0M	$157.8M
YoY Change	71.1%	13.15%
Cash & Equivalents	$94.44M	$112.8M
Short-Term Investments	$55.60M	$45.01M
Other Short-Term Assets	$10.67M	$8.300M
YoY Change	-34.29%	-42.54%
Inventory	$54.59M	$58.23M
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets	$224.0M	$224.3M
YoY Change	0.56%	-2.31%
LONG-TERM ASSETS
Property, Plant & Equipment	$51.47M	$53.48M
YoY Change	-10.0%	-7.96%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets	$14.65M	$15.75M
YoY Change	17.61%	24.13%
Total Long-Term Assets	$85.88M	$95.74M
YoY Change	-8.08%	-1.06%
TOTAL ASSETS
Total Short-Term Assets	$224.0M	$224.3M
Total Long-Term Assets	$85.88M	$95.74M
Total Assets	$309.9M	$320.0M
YoY Change	-1.99%	-1.94%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$86.42M	$103.2M
YoY Change	-35.84%	-30.33%
Accrued Expenses	$5.885M	$5.500M
YoY Change	1.89%	-10.22%
Deferred Revenue	$574.0K
YoY Change	-92.2%
Short-Term Debt	$0.00	$0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$92.30M	$110.1M
YoY Change	-34.49%	-28.62%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$16.13M	$16.90M
YoY Change	-20.46%	-21.66%
Total Long-Term Liabilities	$16.13M	$16.90M
YoY Change	-20.46%	-21.66%
TOTAL LIABILITIES
Total Short-Term Liabilities	$92.30M	$110.1M
Total Long-Term Liabilities	$16.13M	$16.90M
Total Liabilities	$108.4M	$127.0M
YoY Change	-32.72%	-27.78%
SHAREHOLDERS EQUITY
Retained Earnings	$174.6M	$168.8M
YoY Change	24.88%	28.34%
Common Stock	$11.00K	$11.00K
YoY Change	0.0%	0.0%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$201.5M	$193.0M
YoY Change
Total Liabilities & Shareholders Equity	$309.9M	$320.0M
YoY Change	-1.99%	-1.94%

Cashflow Statement

Concept	2023 Q4	2023 Q3
OPERATING ACTIVITIES
Net Income	$6.035M	$23.13M
YoY Change	-77.24%	-36.02%
Depreciation, Depletion And Amortization	$3.307M	$3.500M
YoY Change	11.95%	22.81%
Cash From Operating Activities	$10.56M	$29.90M
YoY Change	-79.6%	-46.02%
INVESTING ACTIVITIES
Capital Expenditures	$983.0K	$1.600M
YoY Change	-89.15%	-190.5%
Acquisitions
YoY Change
Other Investing Activities	-$9.764M	-$44.80M
YoY Change
Cash From Investing Activities	-$10.75M	-$46.40M
YoY Change	18.57%	2524.43%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-17.89M	-18.20M
YoY Change	-26.48%	-59.65%
NET CHANGE
Cash From Operating Activities	10.56M	29.90M
Cash From Investing Activities	-10.75M	-46.40M
Cash From Financing Activities	-17.89M	-18.20M
Net Change In Cash	-18.08M	-34.70M
YoY Change	-198.56%	-507.18%
FREE CASH FLOW
Cash From Operating Activities	$10.56M	$29.90M
Capital Expenditures	$983.0K	$1.600M
Free Cash Flow	$9.574M	$28.30M
YoY Change	-77.57%	-50.49%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q3	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	45009000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	0	usd
CY2023Q3	us-gaap	Inventory Net InventoryNet	58227000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	118856000	usd
CY2023Q3	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	8289000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	16237000	usd
CY2023Q3	us-gaap	Assets Current AssetsCurrent	224276000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	222784000	usd
CY2023Q3	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	53484000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	57185000	usd
CY2023Q3	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	15681000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	18460000	usd
CY2023Q3	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	15753000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	12456000	usd
CY2023Q3	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	10825000	usd
CY2022Q4	us-gaap	Deferred Income Tax Assets Net DeferredIncomeTaxAssetsNet	5328000	usd
CY2023Q3	us-gaap	Assets Assets	320019000	usd
CY2022Q4	us-gaap	Assets Assets	316213000	usd
CY2023Q3	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	103223000	usd
CY2022Q4	us-gaap	Accounts Payable And Accrued Liabilities Current AccountsPayableAndAccruedLiabilitiesCurrent	134690000	usd
CY2023Q3	us-gaap	Taxes Payable Current TaxesPayableCurrent	1417000	usd
CY2022Q4	us-gaap	Taxes Payable Current TaxesPayableCurrent	428000	usd
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	10928000	shares
CY2023Q3	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	10892000	shares
CY2023Q3	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	0	shares
CY2022Q4	us-gaap	Treasury Stock Common Shares TreasuryStockCommonShares	54000	shares
CY2023Q3	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	0	usd
CY2022Q4	us-gaap	Treasury Stock Common Value TreasuryStockCommonValue	6398000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	193035000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	155044000	usd
CY2023Q3	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	320019000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	316213000	usd
	us-gaap	Net Income Loss NetIncomeLoss	93380000	usd
	us-gaap	Net Income Loss NetIncomeLoss	117050000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	9754000	usd
	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	8026000	usd
	med	Operating Lease Expense Non Cash OperatingLeaseExpenseNonCash	3532000	usd
	med	Operating Lease Expense Non Cash OperatingLeaseExpenseNonCash	4740000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	5795000	usd
	us-gaap	Share Based Compensation ShareBasedCompensation	8103000	usd
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-622000	usd
	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	usd
	us-gaap	Other Amortization Of Deferred Charges OtherAmortizationOfDeferredCharges	0	usd
	us-gaap	Other Amortization Of Deferred Charges OtherAmortizationOfDeferredCharges	14000	usd
	us-gaap	Deferred Income Tax Expense Benefit DeferredIncomeTaxExpenseBenefit	-1746000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-60629000	usd
	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-34764000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-7948000	usd
	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1889000	usd
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	4674000	usd
	us-gaap	Increase Decrease In Other Operating Assets IncreaseDecreaseInOtherOperatingAssets	8545000	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-35343000	usd
	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-22259000	usd
	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	989000	usd
	us-gaap	Increase Decrease In Accrued Income Taxes Payable IncreaseDecreaseInAccruedIncomeTaxesPayable	795000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	137135000	usd
	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	142831000	usd
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	0	usd
	us-gaap	Proceeds From Sale And Maturity Of Available For Sale Securities ProceedsFromSaleAndMaturityOfAvailableForSaleSecurities	5267000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	5537000	usd
	us-gaap	Payments To Acquire Property Plant And Equipment PaymentsToAcquirePropertyPlantAndEquipment	7617000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-50316000	usd
	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-2350000	usd
	med	Proceeds From Stock Options Exercised Directors ProceedsFromStockOptionsExercisedDirectors	105000	usd
	med	Proceeds From Stock Options Exercised Directors ProceedsFromStockOptionsExercisedDirectors	0	usd
	us-gaap	Payments For Repurchase Of Other Equity PaymentsForRepurchaseOfOtherEquity	3348000	usd
	us-gaap	Payments For Repurchase Of Other Equity PaymentsForRepurchaseOfOtherEquity	1504000	usd
	us-gaap	Payments Of Dividends PaymentsOfDividends	55039000	usd
	us-gaap	Payments Of Dividends PaymentsOfDividends	53698000	usd
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	3602000	usd
	us-gaap	Payments For Repurchase Of Common Stock PaymentsForRepurchaseOfCommonStock	120048000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-61884000	usd
	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-175250000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	125000	usd
	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	296000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	25060000	usd
	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-34473000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	87691000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	104183000	usd
	us-gaap	Income Taxes Paid IncomeTaxesPaid	30169000	usd
	us-gaap	Income Taxes Paid IncomeTaxesPaid	33906000	usd
	us-gaap	Dividends Cash DividendsCash	19184000	usd
	us-gaap	Dividends Cash DividendsCash	19395000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	155044000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	39968000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions	606000	usd
CY2023Q1	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	105000	usd
CY2023Q1	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	3236000	usd
CY2023Q1	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	3602000	usd
CY2023Q1	us-gaap	Treasury Stock Retired Cost Method Amount TreasuryStockRetiredCostMethodAmount	0	usd
CY2023Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	9000	usd
CY2023Q1	us-gaap	Dividends Common Stock Cash DividendsCommonStockCash	17994000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	170900000	usd
CY2023Q2	us-gaap	Net Income Loss NetIncomeLoss	30280000	usd
CY2023Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions	2514000	usd
CY2023Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	90000	usd
CY2023Q2	us-gaap	Dividends Common Stock Cash DividendsCommonStockCash	18221000	usd
CY2023Q3	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	110000	usd
CY2023Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	18000	usd
CY2023Q3	us-gaap	Dividends Common Stock Cash DividendsCommonStockCash	18240000	usd
CY2023Q3	us-gaap	Stockholders Equity StockholdersEquity	193035000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	202474000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	41781000	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions	2275000	usd
CY2022Q1	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	1459000	usd
CY2022Q1	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	10000000	usd
CY2022Q1	us-gaap	Treasury Stock Retired Cost Method Amount TreasuryStockRetiredCostMethodAmount	0	usd
CY2022Q1	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	16000	usd
CY2022Q1	us-gaap	Dividends Common Stock Cash DividendsCommonStockCash	19063000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	216024000	usd
CY2022Q2	us-gaap	Net Income Loss NetIncomeLoss	39113000	usd
CY2022Q2	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions	2865000	usd
CY2022Q2	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	20000	usd
CY2022Q2	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	90038000	usd
CY2022Q2	us-gaap	Treasury Stock Retired Cost Method Amount TreasuryStockRetiredCostMethodAmount	1000	usd
CY2022Q2	med	Adjustments To Paid In Capital Share Repurchases Not Yet Settled AdjustmentsToPaidInCapitalShareRepurchasesNotYetSettled	20010000	usd
CY2022Q2	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	141000	usd
CY2022Q2	us-gaap	Dividends Common Stock Cash DividendsCommonStockCash	18598000	usd
CY2022Q2	us-gaap	Stockholders Equity StockholdersEquity	129476000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	36155000	usd
CY2022Q3	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation And Exercise Of Stock Options AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationAndExerciseOfStockOptions	2963000	usd
CY2022Q3	us-gaap	Adjustments Related To Tax Withholding For Share Based Compensation AdjustmentsRelatedToTaxWithholdingForShareBasedCompensation	25000	usd
CY2022Q3	us-gaap	Treasury Stock Value Acquired Cost Method TreasuryStockValueAcquiredCostMethod	20010000	usd
CY2022Q3	us-gaap	Treasury Stock Retired Cost Method Amount TreasuryStockRetiredCostMethodAmount	0	usd
CY2022Q3	us-gaap	Accelerated Share Repurchase Program Adjustment AcceleratedShareRepurchaseProgramAdjustment	20010000	usd
CY2022Q3	us-gaap	Other Comprehensive Income Loss Net Of Tax Portion Attributable To Parent OtherComprehensiveIncomeLossNetOfTaxPortionAttributableToParent	123000	usd
CY2022Q3	us-gaap	Dividends Common Stock Cash DividendsCommonStockCash	18170000	usd
CY2022Q3	us-gaap	Stockholders Equity StockholdersEquity	150522000	usd
	us-gaap	Use Of Estimates UseOfEstimates	<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:700;line-height:120%">Use of Estimates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - The preparation of financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of revenue and expenses during the reporting period. Actual results could differ materially from those estimates.</span>
CY2023Q3	us-gaap	Inventory Raw Materials InventoryRawMaterials	8491000	usd
CY2022Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	12670000	usd
CY2023Q3	us-gaap	Retail Related Inventory Packaging And Other Supplies RetailRelatedInventoryPackagingAndOtherSupplies	2269000	usd
CY2022Q4	us-gaap	Retail Related Inventory Packaging And Other Supplies RetailRelatedInventoryPackagingAndOtherSupplies	3611000	usd
CY2023Q3	med	Inventory Non Food Finished Goods InventoryNonFoodFinishedGoods	4426000	usd
CY2022Q4	med	Inventory Non Food Finished Goods InventoryNonFoodFinishedGoods	8738000	usd
CY2023Q3	us-gaap	Inventory Finished Goods InventoryFinishedGoods	49558000	usd
CY2022Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	97675000	usd
CY2023Q3	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	6517000	usd
CY2022Q4	us-gaap	Inventory Valuation Reserves InventoryValuationReserves	3838000	usd
CY2023Q3	us-gaap	Inventory Net InventoryNet	58227000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	118856000	usd
CY2023Q3	us-gaap	Net Income Loss NetIncomeLoss	23131000	usd
CY2022Q3	us-gaap	Net Income Loss NetIncomeLoss	36155000	usd
	us-gaap	Net Income Loss NetIncomeLoss	93380000	usd
	us-gaap	Net Income Loss NetIncomeLoss	117050000	usd
CY2023Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	10892000	shares
CY2022Q3	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	10964000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	10881000	shares
	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	11290000	shares
CY2023Q3	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	41000	shares
CY2022Q3	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	78000	shares
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	44000	shares
	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	79000	shares
CY2023Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	10933000	shares
CY2022Q3	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	11042000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	10925000	shares
	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	11369000	shares
CY2023Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	2.12
CY2022Q3	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	3.30
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	8.58
	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	10.37
CY2023Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	2.12
CY2022Q3	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	3.27
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	8.55
	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	10.30
	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Lower Range Limit ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeLowerRangeLimit	26.52
	us-gaap	Share Based Compensation Shares Authorized Under Stock Option Plans Exercise Price Range Upper Range Limit ShareBasedCompensationSharesAuthorizedUnderStockOptionPlansExercisePriceRangeUpperRangeLimit	66.68
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	0	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	33000	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	54.98
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	33000	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	54.98
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	4000	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	27.18
	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	29000	shares
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	58.65
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	33000	shares
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	54.98
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	29000	shares
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	58.65
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	28000	shares
CY2022Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	52.76
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P3Y9M18D
	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P3Y9M18D
CY2023Q3	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	500000	usd
CY2023Q3	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	500000	usd
	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	100000	usd
	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercises In Period Total Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisesInPeriodTotalIntrinsicValue	300000	usd
CY2023Q3	us-gaap	Stock Issued During Period Shares Share Based Compensation StockIssuedDuringPeriodSharesShareBasedCompensation	258000	shares
CY2023Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2675000	usd
CY2022Q3	us-gaap	Stock Issued During Period Shares Share Based Compensation StockIssuedDuringPeriodSharesShareBasedCompensation	156000	shares
CY2022Q3	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2963000	usd
	us-gaap	Stock Issued During Period Shares Share Based Compensation StockIssuedDuringPeriodSharesShareBasedCompensation	258000	shares
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	5795000	usd
	us-gaap	Stock Issued During Period Shares Share Based Compensation StockIssuedDuringPeriodSharesShareBasedCompensation	156000	shares
	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	8103000	usd
CY2022Q3	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	400000	usd
	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	400000	usd
	us-gaap	Employee Service Share Based Compensation Tax Benefit From Compensation Expense EmployeeServiceShareBasedCompensationTaxBenefitFromCompensationExpense	1200000	usd
CY2022Q3	us-gaap	Operating Lease Expense OperatingLeaseExpense	1700000	usd
	us-gaap	Operating Lease Expense OperatingLeaseExpense	3900000	usd
	us-gaap	Operating Lease Expense OperatingLeaseExpense	5200000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	4838000	usd
	us-gaap	Operating Lease Payments OperatingLeasePayments	5413000	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	753000	usd
	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	103000	usd
CY2023Q3	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P4Y2M
CY2023Q3	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.0200
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	1435000	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	5955000	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	6095000	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Three LesseeOperatingLeaseLiabilityPaymentsDueYearThree	4438000	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due Year Four LesseeOperatingLeaseLiabilityPaymentsDueYearFour	2553000	usd
CY2023Q3	med	Lessee Operating Lease Liability Payments Due After Year Four LesseeOperatingLeaseLiabilityPaymentsDueAfterYearFour	2858000	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	23334000	usd
CY2023Q3	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	990000	usd
CY2023Q3	us-gaap	Operating Lease Liability OperatingLeaseLiability	22344000	usd
CY2023Q3	us-gaap	Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax	150000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Foreign Currency Translation Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossForeignCurrencyTranslationAdjustmentNetOfTax	24000	usd
CY2023Q3	us-gaap	Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	-9000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Available For Sale Securities Adjustment Net Of Tax AccumulatedOtherComprehensiveIncomeLossAvailableForSaleSecuritiesAdjustmentNetOfTax	0	usd
CY2023Q3	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	141000	usd
CY2022Q4	us-gaap	Accumulated Other Comprehensive Income Loss Net Of Tax AccumulatedOtherComprehensiveIncomeLossNetOfTax	24000	usd
CY2023Q3	us-gaap	Debt Securities Available For Sale Accumulated Gross Unrealized Gain Loss Before Tax DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax	-9000	usd
CY2023Q3	us-gaap	Interest Receivable InterestReceivable	301000	usd
CY2023Q3	us-gaap	Cash And Cash Equivalents Fair Value Disclosure CashAndCashEquivalentsFairValueDisclosure	112751000	usd
CY2023Q3	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	45009000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents And Short Term Investments CashCashEquivalentsAndShortTermInvestments	87691000	usd
CY2022Q4	us-gaap	Debt Securities Available For Sale Accumulated Gross Unrealized Gain Loss Before Tax DebtSecuritiesAvailableForSaleAccumulatedGrossUnrealizedGainLossBeforeTax	0	usd
CY2022Q4	us-gaap	Interest Receivable InterestReceivable	0	usd
CY2022Q4	med	Cash Cash Equivalents And Short Term Investments Fair Value Disclosure CashCashEquivalentsAndShortTermInvestmentsFairValueDisclosure	87691000	usd
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	87691000	usd
CY2022Q4	us-gaap	Available For Sale Securities Debt Securities Current AvailableForSaleSecuritiesDebtSecuritiesCurrent	0	usd
	us-gaap	Debt And Equity Securities Realized Gain Loss DebtAndEquitySecuritiesRealizedGainLoss	0	usd
CY2023Q3	us-gaap	Debt And Equity Securities Realized Gain Loss DebtAndEquitySecuritiesRealizedGainLoss	0	usd
CY2022Q3	us-gaap	Debt And Equity Securities Realized Gain Loss DebtAndEquitySecuritiesRealizedGainLoss	0	usd
	us-gaap	Debt And Equity Securities Realized Gain Loss DebtAndEquitySecuritiesRealizedGainLoss	0	usd
CY2022Q2	us-gaap	Stock Repurchase Program Authorized Amount1 StockRepurchaseProgramAuthorizedAmount1	100000000	usd
CY2022Q2	us-gaap	Treasury Stock Shares Acquired TreasuryStockSharesAcquired	480000	shares
CY2022Q3	us-gaap	Treasury Stock Shares Acquired TreasuryStockSharesAcquired	91000	shares

Files In Submission

Name	View Source	Status
med-20230930_def.xml	Edgar Link	unprocessable
med-20230930_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
med-20230930_cal.xml	Edgar Link	unprocessable
med-20230930_lab.xml	Edgar Link	unprocessable
0001628280-23-037080-index-headers.html	Edgar Link	pending
0001628280-23-037080-index.html	Edgar Link	pending
0001628280-23-037080.txt	Edgar Link	pending
0001628280-23-037080-xbrl.zip	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
med-20230930.htm	Edgar Link	pending
med-20230930.xsd	Edgar Link	pending
med-20230930xexx311.htm	Edgar Link	pending
med-20230930xexx312.htm	Edgar Link	pending
med-20230930xexx321.htm	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
med-20230930_htm.xml	Edgar Link	completed
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$MED
MEDIFAST INC Stock $med

2023 Q4 Form 10-Q Financial Statement

#000162828023037080 Filed on November 06, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MED MEDIFAST INC Stock $med

2023 Q4 Form 10-Q Financial Statement

#000162828023037080 Filed on November 06, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$MED
MEDIFAST INC Stock $med